Sotera Health (NASDAQ:SHC) Issues FY 2024 Earnings Guidance

Sotera Health (NASDAQ:SHC) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.670-0.750 for the period, compared to the consensus EPS estimate of 0.720. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Sotera Health also updated its FY24 guidance to $0.67-0.75 EPS.

Sotera Health Stock Performance

Shares of SHC traded down $0.50 during mid-day trading on Tuesday, hitting $15.30. 1,110,260 shares of the company traded hands, compared to its average volume of 1,303,453. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. The stock has a 50-day moving average price of $15.95 and a two-hundred day moving average price of $13.64. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.44. The stock has a market cap of $4.33 billion, a price-to-earnings ratio of 105.50 and a beta of 2.08.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Monday, August 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.04. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. The business had revenue of $277.00 million during the quarter, compared to analysts’ expectations of $266.45 million. During the same period in the prior year, the company earned $0.19 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis. Equities analysts anticipate that Sotera Health will post 0.64 earnings per share for the current year.

Analysts Set New Price Targets

SHC has been the subject of a number of research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a report on Tuesday, August 6th. Barclays upped their target price on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.70.

Insiders Place Their Bets

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now directly owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 55.12% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.